Synlogic (SYBX) Stock Forecast, Price & News

Synlogic (NASDAQ:SYBX) Frequently Asked Questions

Is Synlogic a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic or view top-rated stocks.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Synlogic.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) posted its quarterly earnings results on Thursday, May, 12th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Synlogic had a negative net margin of 3,067.42% and a negative trailing twelve-month return on equity of 43.07%. During the same quarter in the previous year, the company posted ($0.36) EPS.
View Synlogic's earnings history.

When did Synlogic's stock split? How did Synlogic's stock split work?

Shares of Synlogic reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

5 equities research analysts have issued 1-year target prices for Synlogic's stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Synlogic's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 627.3% from the stock's current price.
View analysts' price targets for Synlogic or view top-rated stocks among Wall Street analysts.

Who are Synlogic's key executives?

Synlogic's management team includes the following people:

• Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc, Pres, CEO & Director (Age 46, Pay $891.42k)
• Mr. Antoine Awad, Chief Operating Officer (Age 42, Pay $572.92k)
• Dr. Timothy K. Lu M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 41)
• Dr. James J. Collins Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 56)
• Mr. Michael Jensen, Chief Financial Officer
• Dr. David L. Hava Ph.D., Chief Scientific Officer (Age 47)
• Dr. Elizabeth Wolffe, Head of Investor Relations & Corp. Communications
• Mr. Daniel Rosan, Sr. VP & Head of Investor Relations
• Mr. Brendan St. Amant, Head of Legal
• Mr. Adam Thomas, Chief People Officer & Sec.

Who are some of Synlogic's key competitors?

Some companies that are related to Synlogic include Edgewise Therapeutics (EWTX), Silence Therapeutics (SLN), Seres Therapeutics (MCRB), InterCure (INCR), Radius Health (RDUS), Phathom Pharmaceuticals (PHAT), Precigen (PGEN), Alpine Immune Sciences (ALPN), Enochian Biosciences (ENOB), Theseus Pharmaceuticals (THRX), Verona Pharma (VRNA), AC Immune (ACIU), Provention Bio (PRVB), Lexicon Pharmaceuticals (LXRX) and Biotech Acquisition (BIOT).
View all of SYBX's competitors.

What other stocks do shareholders of Synlogic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Who are Synlogic's major shareholders?

Synlogic's stock is owned by many different retail and institutional investors. Top institutional investors include Alyeska Investment Group L.P. (3.69%), Vanguard Group Inc. (3.22%), Dimensional Fund Advisors LP (0.85%), Harbor Capital Advisors Inc. (0.51%), State Street Corp (0.18%) and Northern Trust Corp (0.13%). Company insiders that own Synlogic stock include Antoine Awad, Aoife Brennan and Michael Vangsted Jensen.
View institutional ownership trends for Synlogic.

Which major investors are selling Synlogic stock?

SYBX stock was sold by a variety of institutional investors in the last quarter, including Harbor Capital Advisors Inc., Acadian Asset Management LLC, Dimensional Fund Advisors LP, Vanguard Group Inc., and Simplex Trading LLC. Company insiders that have sold Synlogic company stock in the last year include Antoine Awad, and Aoife Brennan.
View insider buying and selling activity for Synlogic or view top insider-selling stocks.

Which major investors are buying Synlogic stock?

SYBX stock was acquired by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., State Street Corp, UBS Group AG, Ensign Peak Advisors Inc, UMA Financial Services Inc., Northern Trust Corp, and Group One Trading L.P..
View insider buying and selling activity for Synlogic or or view top insider-buying stocks.

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $1.10.

How much money does Synlogic make?

Synlogic has a market capitalization of $77.28 million and generates $1.75 million in revenue each year. The biotechnology company earns $-60.56 million in net income (profit) each year or ($1.00) on an earnings per share basis.

How many employees does Synlogic have?

Synlogic employs 84 workers across the globe.

What is Synlogic's official website?

The official website for Synlogic is www.synlogictx.com.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at (617) 401-9975, via email at [email protected], or via fax at 512-681-5201.